Efficacy of acamprosate in the treatment of alcohol-dependent outpatients
Open accessThe DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the efficacy and security of acamprosate in the treatment of 75 men, aged 18 to 59 years, with diagnosis of alcohol dependence according to the ICD-10. METHODS: Double-blind, placebo-controlled study, 24-week long. After a one-week detoxification period, patients were randomly divided in two groups: the first group received acamprosate (six tablets of 333 mg/d for 12 weeks) and the second group received placebo (six tablets for 12 weeks). After the first 12 weeks, patients continued the follow-up for further 12 weeks without medication. RESULTS: Patients who were receiving acamprosate showed significantly higher continuous abstinence time within the 24 weeks of treatment compared with patients who were assigned to placebo treatment (p=.017). Twenty-five percent of patients who were receiving acamprosate and 20% of the placebo-treated patients dropped out. Few side-effects were reported in both groups. CONCLUSION: Acamprosate proved to be safe and effective in treating alcohol-dependent patients and to maintain the abstinence during 24 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“One included pharmacologic trials with 75 participants reported on adverse events across study conditions. Baltieri 2003 reported the proportion of each study condition that experienced specific side effects including diarrhea, pruritis, polyuria, and headache. Although no statistical examination comparing reported side effects was conducted, the proportion of the sample that experienced headaches”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Baltieri 2003
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One included pharmacologic trial with a total of 75 participants reported on remission (Baltieri 2003). Baltieri and colleagues study identified a marginally significant increase in the probability of self‐reported remission attributable to acamprosate as compared to placebo at six months (risk ratio (RR) = 2.13, 95% confidence Interval (CI) 1.00 to 4.52; Analysis 1.1).”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Baltieri 2003
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Incomplete outcome data (attrition bias) All outcomes Low risk”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Baltieri 2003
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three included pharmacologic trials with 247 participants reported on retention in treatment (Baltieri 2003; Chompookham 2018; Furieri 2007). None of these studies identified a significant difference in the likelihood of retention comparing acamprosate or gabapentin to placebo (RR = 1.13, 95% CI 0.89 to 1.44; Heterogeneity: Tau² = 0.02; Q = 3.67, df = 2 (P = 0.16); I² = 46%; low‐certainty evidence”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Baltieri 2003
The cited source says what the claim attributes to it.
In the citing paper
“Allocation concealment (selection bias) Unclear risk”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Baltieri 2003
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Statistics for Medical Research
Newcombe, R. G. (1992) · Journal of Epidemiology and Community Health · doi:10.1136/jech.46.5.549-a · Cited by 981
Relapse Prevention by Acamprosate: Results From a Placebo-Controlled Study on Alcohol Dependence
Sass, H. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830080023006 · Cited by 479
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence
Whitworth, A. B., Oberbauer, H., Fleischhacker, W. W., Lesch, O. M., Walter, H., Nimmerrichter, A., Platz, T., Fischer, F., & Potgieter, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91682-7 · Cited by 320
Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat
Spanagel, R., Hölter, S. M., Allingham, K., Landgraf, R., & Zieglgänsberger, W. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00174-4 · Cited by 274
DOUBLE-BLIND RANDOMIZED MULTICENTRE TRIAL OF ACAMPROSATE IN MAINTAINING ABSTINENCE FROM ALCOHOL
(1995) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a045720 · Cited by 273
Chick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.2.176 · Cited by 213
Pelc, I., Verbanck, P., Bon, O. L., Gavrilovic, M., Lion, K., & Lehert, P. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.1.73 · Cited by 184
Acamprosate in alcohol dependence: how does it work?
LITTLETON, J. (1995) · Addiction · doi:10.1111/j.1360-0443.1995.tb01088.x · Cited by 178
Zeise, M. L., Kasparov, S., Capogna, M., & Zieglgänsberger, W. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90682-8 · Cited by 175
ABILITY OF CALCIUM BIS ACETYL HOMOTAURINE, A GABA AGONIST, TO PREVENT RELAPSE IN WEANED ALCOHOLICS
Lhuintre, J.-P., Moore, N., Saligaut, C., Boismare, F., Daoust, M., Chretien, P., Tran, G., & Hillemand, B. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91615-0 · Cited by 166
Research works printed but not linked: 5
- Scivoletto S, 1993, Tratamento farmacológico das drogadependências, 107
- Cornish JW, 2001, Treatment of substance-related disorders, 519
- Nalpas B, 1990, L'Acamprosate, De la pharmacologie à la clinique. Encephale, 16, 175
- Spanagel R, 1996, Acamprosate and alcohol: I, Eur J Pharmacol, 305, 39
- Altman DG, 1991, Analysis of Survival Times, 365
Cited by
Treatment and prevention of mental disorders in low-income and middle-income countries
Patel, V., Araya, R., Chatterjee, S., Chisholm, D., Cohen, A., De Silva, M., Hosman, C., McGuire, H., Rojas, G., & van Ommeren, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61240-9 · Cited by 930
Rösner, S., Leucht, S., Lehert, P., & Soyka, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107078308 · Cited by 300
Anticonvulsants for alcohol withdrawal
Minozzi, S., Amato, L., Vecchi, S., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005064.pub3 · Cited by 170
Donoghue, K., Zerbi, C. E., Saunders, R., Whittington, C. J., Pilling, S., & Drummond, C. (2015) · Addiction · doi:10.1111/add.12875 · Cited by 127
Medical Treatment of Alcohol Dependence: A Systematic Review
Miller, P. M., Book, S. W., & Stewart, S. H. (2011) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.42.3.b · Cited by 107
Metadata
- Authors
- Baltieri, D. A., & Andrade, A. G. D.
- Affiliations
- University of São Paulo, Brazil
- Universidade de São Paulo (BR)
- Venue
- Revista Brasileira de Psiquiatria
- Publisher
- EDITORA SCIENTIFIC
- Published
- 2003-09
- Volume
- 25
- Issue
- 3
- Pages
- 156-159
- ISSN
- 1516-4446 (ISSN-L)
- OpenAlex
- W2082030731
- Semantic Scholar
- b00be5be13c381aafd290f90b9fdbabfbf06977f
- Cited by
- 33
- References
- 27
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2016: 1 · 2015: 1 · 2012: 2
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Brazilian Journal of Psychiatry (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- The Scientific Electronic Library Online (Fundação de Amparo à Pesquisa do Estado de São Paulo) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- acamprosate, alcoholism, alcoholism treatment, abstinence maintenance, outpatients, detoxification, drug efficacy, drug safety, adverse effects
- MeSH terms
- Acamprosate, Adolescent, Adult, Alcohol Deterrents, Alcoholism, Ambulatory Care, Double-Blind Method, Follow-Up Studies, Humans, Male, Middle Aged, Taurine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of acamprosate in the treatment of alcohol-dependent outpatients. https://app.cochat.ai/papers/10.1590/s1516-44462003000300007
- The paper
- Baltieri, D. A., & Andrade, A. G. D. (2003). Efficacy of acamprosate in the treatment of alcohol-dependent outpatients. Revista Brasileira de Psiquiatria. https://doi.org/10.1590/s1516-44462003000300007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.